Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday

Novartis U.S.-listed shares fell 13% after experimental myotonic-dystrophy therapy del-desiran failed to improve a key patient indicator, following a separate failure of its cardiovascular-risk drug. Amgen declined 9% because it is developing a similar cholesterol-targeting treatment, adding pressure to the Dow given its fourth-largest index weighting. Novartis reiterated its expectation for 5%-6% sales CAGR through 2030, but the trial setbacks raise risks around its pipeline and future product contributions.

Analysis

The NVS drawdown should be viewed as a pipeline-NPV reset rather than a near-term earnings impairment: its marketed portfolio and stated medium-term sales trajectory are largely unchanged, but two recent setbacks reduce confidence in management’s ability to replenish growth beyond the current franchise cycle. The more important second-order effect is likely a higher risk premium on early and mid-stage neuromuscular assets across biotech, particularly programs relying on biomarker improvement as a proxy for functional benefit. Over the next 1-3 months, NVS may remain technically pressured as generalist holders reassess whether its premium multiple adequately compensates for development risk.

AMGN’s reaction is a read-through on the entire Lp(a)-lowering hypothesis, but the market may be conflating target validation with a single program’s molecule, patient selection, duration, and endpoint design. If AMGN’s cardiovascular-outcomes protocol delivers materially deeper or more durable Lp(a) reduction in a higher-risk population, its asset can still retain substantial strategic value; however, the probability-adjusted peak-sales estimate and terminal multiple should both compress until comparative trial details are available. This creates a binary information vacuum rather than a confirmed fundamental impairment, making trial-design disclosure the critical catalyst over coming weeks.

Contrarian setup: AMGN’s selloff could prove excessive if Lp(a) represented only a modest portion of its pre-event enterprise value, while NVS’s decline may be more durable because consecutive misses raise platform and capital-allocation questions. The thesis is falsified if detailed data show that the cardiovascular failure was driven by a class-wide disconnect between Lp(a) reduction and clinical outcomes, or if regulators/public investigators identify a safety or mechanistic issue relevant to AMGN’s program. For NVS, a downward revision to 2026-30 growth guidance or incremental pipeline discontinuations would indicate that the market has not fully discounted the damage.

Key Decisions for Investors

• Do not add to NVS on the initial decline; maintain an underweight or use rallies over the next 1-3 months to reduce exposure. Reassess only after management quantifies remaining pipeline peak-sales assumptions and confirms that long-range sales guidance does not require incremental business-development spend; a guidance cut is the key downside trigger.
• Place AMGN on a long-watch list rather than treating the move as an immediate short: initiate only after trial-design and subgroup details establish meaningful differentiation from the failed program. A 3-6 month rebound trade is attractive if the Lp(a) asset accounts for less than roughly 5-7% of implied enterprise value loss, with exit discipline on any evidence of class-wide efficacy failure.
• For sector hedging, favor a relative-value position of long diversified large-cap pharma exposure via XLV against a modest NVS underweight rather than a broad biotech short. The likely transmission is higher valuation dispersion among single-asset or biomarker-dependent developers, not a broad deterioration in established-pharma earnings.
• Monitor AMGN implied volatility and forthcoming clinical-data releases; if volatility remains elevated after design differentiation is confirmed, selling downside premium through defined-risk put spreads may offer better risk/reward than outright equity exposure. Avoid this structure until the remaining event calendar and protocol overlap are verified.